The Clinical Phenotyping Resource and Biobank Core (C-PROBE) ofthe University of Michigan George M. O'Brien Kidney Center is designed to expedite the application of nascent laboratory discoveries to human subjects in the quest to treat and prevent and kidney disease. The primary goal ofthe C-PROBE is to provide infrastructure that will optimize the interface between patients and biomedical investigators to streamline translational research in kidney disease.
Specific Aims : C-PROBE will 1) maintain a cohort of 1000 adult participants with kidney disease from diverse backgrounds from University of Michigan, Renaissance Renal Research Institute, University of Illinois, Chicago, Wayne State University and Temple University 2) add 300 pediatric participants with kidney disease from University of Michigan and Levine Children's Hospital, Charlotte, NC, to enhance scientific exploration and collaboration on affected individuals throughout the life span 3) provide longitudinal phenotypic characterization ofthe C-PROBE cohort (including demographic, clinical and laboratory data) utilizing a multi-dimensional relational clinical research data management system, VELOS eResearch?, to promote and support translational investigation 4) maintain a specimen biobank for the purpose of sharing and distributing urine, blood, DNA, and kidney biopsy tissue samples to biomedical research investigators according to agreed repository governance policies 5) support high-quality research by linking biostatistical and bioinformatics expertise from the Applied Systems Biology and Bioinformatics Cores to investigators engaged in ancillary studies utilizing core resources. Methods: C-PROBE will provide (a) a longitudinal cohort of well-characterized patients with kidney disease organized into a secured, web-distributed clinical research data management system; (b) a specimen repository integrated into the clinical research database for distribution and sharing with investigators according to agreed policies; (c) access to study design and analytical expertise for ancillary projects utilizing core materials. C-PROBE leverages support from the Michigan Institute for Clinical and Health Research (Michigan CTSA) to accelerate translational research productivity. .
C-PROBE is structured and governed to optimally harness and maximize the use of resources for conducting translational research in kidney disease. Given the collaborative multi-disciplinary network of scientific expertise, this core is singularly suitable to accelerate medical advancement to address the public health burden of kidney disease.
| Heinzel, Andreas; Kammer, Michael; Mayer, Gert et al. (2018) Validation of Plasma Biomarker Candidates for the Prediction of eGFR Decline in Patients With Type 2 Diabetes. Diabetes Care 41:1947-1954 |
| Wernisch, Stefanie; Afshinnia, Farsad; Rajendiran, Thekkelnaycke et al. (2018) Probing the application range and selectivity of a differential mobility spectrometry-mass spectrometry platform for metabolomics. Anal Bioanal Chem 410:2865-2877 |
| Mariani, Laura H; Martini, Sebastian; Barisoni, Laura et al. (2018) Interstitial fibrosis scored on whole-slide digital imaging of kidney biopsies is a predictor of outcome in proteinuric glomerulopathies. Nephrol Dial Transplant 33:310-318 |
| Verma, Rakesh; Venkatareddy, Madhusudan; Kalinowski, Anne et al. (2018) Nephrin is necessary for podocyte recovery following injury in an adult mature glomerulus. PLoS One 13:e0198013 |
| Troost, Jonathan P; Trachtman, Howard; Nachman, Patrick H et al. (2018) An Outcomes-Based Definition of Proteinuria Remission in Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol 13:414-421 |
| Breyer, Matthew D; Kretzler, Matthias (2018) Novel avenues for drug discovery in diabetic kidney disease. Expert Opin Drug Discov 13:65-74 |
| Nair, Viji; Komorowsky, Claudiu V; Weil, E Jennifer et al. (2018) A molecular morphometric approach to diabetic kidney disease can link structure to function and outcome. Kidney Int 93:439-449 |
| Zhong, Fang; Chen, Zhaohong; Zhang, Liwen et al. (2018) Tyro3 is a podocyte protective factor in glomerular disease. JCI Insight 3: |
| Galla, S; Chakraborty, S; Cheng, X et al. (2018) Disparate effects of antibiotics on hypertension. Physiol Genomics 50:837-845 |
| Brosius, Frank C; Ju, Wenjun (2018) The Promise of Systems Biology for Diabetic Kidney Disease. Adv Chronic Kidney Dis 25:202-213 |
Showing the most recent 10 out of 178 publications
